Metabolomic analysis reveals widespread metabolic changes driven by NPM-ALK signaling. (A) Unsupervised hierarchical clustering of all identified mass spectral features in DMSO- and CEP-treated cells (D1-D4 are DMSO samples; C1-C4 are CEP samples). (B) Supervised hierarchical clustering of those mass spectral features that changed significantly (P < .05) based on CEP treatment. (C) MetaboAnalyst 2.0–generated pathways that changed in response to ALK inhibition. *P < .05, **P < .01.